Newly elected superintendent speaks at State Board of Education meeting
Catherine Truitt, the state's newly elected superintendent, is expected to speak at the state board of education meeting. Truitt will replace Mark Johnson, who did not seek re-election, and had a combative relationship with the board.
and business operations. Remind our visitors and online listeners that you can follow me online and see all of our materials by going to SPE meetings at State board. I didn't see public schools, so members you reminded that it's our duty to avoid conflicts of interest in the parent's place of interest. As we handle the work of this born, any member of the board know of any conflict of interest or the appearance of conflict. But any matters coming before this meeting, it's so please taken for the record. During the course of the meeting, you become aware of an actual or apparent conflict adventures. Please bring the matter to the attention of the chair. It will then be your duty to abstain from participating in discussion on the matter and somebody on this time I called my colleague Mr Joe Cabinets the latest pledge of Allegiance. Thank you, Chair. Davis, if we'll all rise wherever we are, I pledge allegiance to the flag. E A, uh, thank you. Now come to our special break. Certainly shake for January, meeting our incoming local board adviser, Miss Brenda Stevens, the Orange County Board of Education and the Damon Board later will be joining the board today. We bid farewell to our current advisor. Mr. Mantei Herring, vice chair of the Columbus County Board of Education, concludes this service to the board of this meeting. Half of my colleagues and all of our students I'd like to extend your appreciation to Mr Herring for his service and offered him an opportunity to share a few words. Mr Herring. Thank you, Mr Chairman, can you hear me? Yes, sir. I would like to take this opportunity to thank the North Carolina School Board Association for giving me this opportunity. Uh, it's a humbling experience to know that your name will be associated with men and women who championed education throughout North North Carolina for the past two or three decades. So it's an honor. But to be able to be an adviser on the school board from the first time we had our meeting, I think some of your colleagues or you may have told me that it was the longest meeting if you had had until now, what challenging experiences that we've faced. But, you know, it's reminded me sometimes that, uh, you know, you have to put your you have to make your opinions known. And sometimes what you decide is board members are not going to be championed by all. But the thing to remember is that when we are doing for the Children of North Carolina, what's meant to be done to make them better citizens. It's an honor and a privilege. And I just thank you and thank your colleagues for giving me this opportunity. And I just wish the best and godspeed to the Board of Education. Thank you, Mr Herring. We appreciate your service, uh, adviser to this board and you're continued leadership with the students of Columbus County. We wish you all the best. Thanks. So much mhm this time. I like to recognize Deputy Superintendent Dr Vegas to go. The highlight of Distinguished Award granted to our very own exactly stops are just a call. Good morning. Chair Davis, Vice Chair Duncan. Superintendent Johnson, Members of the board. It's obviously with great pleasure that I bring to your attention. The Carolina T. Saul has awarded Zach Lee Socks stocks the S L Title three consultant in the Standards, Curriculum and Instruction division, the Distinguished Service Award. And it's in recognition of her outstanding service to the profession of E. S L. Just for clarification. T. Saul stands for teachers of English to speakers of other languages. Educators from the field nominated sadly for this award, and I would like to read a few of the comments from them really quick, one colleague said. Exactly. And 28 teens, Atlee had the initiative to start the E l Teacher network. The E ELT Teacher network has a blogged, a YouTube playlist, a wake lit collection of the Twitter chats, a Facebook group and even a hub in Goat Open N. C. We continue to grow and to build capacity. All of all of these have been made possible, thanks to us, at least wonderful leadership and another colleague set of Shared with us. She cares about our students. She cares about us as educators, and she has a passion and a concern for our social emotional well being equal to that of our teaching skills. Knowing that happy, healthy teachers are integral to the success of RL's at this time, I'd like to invite, sadly to say a few words. If she would thank you, Dr Steagall. Good morning, everyone. I'm honored to be with you this morning sharing this recognition. I'm grateful for my divisions. Leadership, Doctor Steagall Doctor moving next doctor day. They got and support the initiatives that we education consultants developed to support all our dedicate er's And I'm really grateful. I've been at the department for four years. On when I was in the classroom as an S L teacher, I was never aware of all the great opportunities that were being developed at the department for teachers. So when I came to the department, it was my goal to share this with the field to say we're working hard for you and we want you to succeed because we know that when you succeed, our students succeed as well. So I'm really, um, honor for this recognition. Thank you for sharing this today here on day. I'm grateful because these shows that what we're doing is reaching out to all educators were growing the community of practice. We call it the L Teacher Network is growing, and it's across the state, and we have a leadership team working really hard to reach out to more educators. So I really have to say this and thank you very much and have a wonderful day. Thank you, sadly. And I, for one, extremely honored to work alongside her. And she's she's model for the rest of us. How to lead with integrity. So thank you. Sadly, thank you, Trista, like a Dr Jekyll and Mr Stocks weak. And our congratulations to well deserved award, which reflects your individual contributions but also your example of the dedicated and then and high quality service that so many of the members of D P I staff and educators across North Carolina provide our students. You're a great example for all of us to follow. Thanks so much. Yeah, The next item concerns receiving regular Cove in 19 updates, which are important to informing our decisions on current future school operation. These updates are particularly important to advise education leaders as science must drive critical policy decisions for this state board as well as our local wards of education and other education leaders. Today we will hear from our partners with the North Carolina Department of Health and Human Services, as well as reflections and practices from Union County in one of our regional case managers. We'll begin with Chief Deputy Secretary Susan Gil Ferry and her colleagues from the North Carolina Department of Health and Human Services. It definitely helped her. They Good morning, everyone. It's wonderful to be with you all today. As always, we have a pretty full deck today, so I'm going to jump right in. But Chairman Davis is always thank you for the great partnership with you and with our colleagues at the Department of Public Instruction. We are delighted to continue to work together as we move forward in our covert response. And I'm going to start really quickly with just a look at where we are today. As we always dio I will say, Um, I think everybody is aware that we are We, like most of the rest of the nation are are seeing increased number of cases. On the positive side, we are seeing significantly increased testing, so that's positive. However, we are concerned because our percent positive continues. Thio escalate So and I am anticipating a fairly significant jump today as well. So overall are trends are trending up in cases up in our percent positive. Um and obviously we're also very concerned about our hospital capacity, Aziz. More folks as we as we continue to see more admissions into the hospital on more folks in I C U. So again, like most of the nation, I think you hear ah lot of concern about where we are right now. Um, with the Koven pandemic, and we are continuing to watch those very, very closely and consider all the different tools that we have. Thio try to continue to slow the spread, of course, starting primarily with as always, prevention and E would be remiss in not reminding us all of the importance of getting behind the mask and showing our leadership by practicing the three W's every day. Next slide, please. And again, this just shows the upward trajectory of cases by age group. And as you can see, the 18 to 24 year old group continues to be the highest number of cases increased cases. However, everyone else is catching up quickly, although as we have seen throughout the pandemic, the number of cases among Children 0 to 17 is the lowest among all age groups. Next slide, please. Um and we like Thio keep in front of you what we're seeing with our our K 12 clusters. I think Dr Tilson presented last time and really showed the evidence and the research behind what we know about Children and what we know about schools and co vid a Z. You see there we continue to see relatively low numbers of clusters in school, and that's a really positive thing. What that tells us is that the protocols that that schools have in place thio slow the spread and keep the infection from spreading among staff and students is working. And that just shows you where we're at currently with our total number of clusters. So next slide, please. And again, we've talked about this a couple of times. Now I just s So it's helpful to see the breakdown so you can see that among are currently active clusters. We have 13 clusters and traditional public schools and two clusters and charter schools. But again, on we've seen some media coverage on this can continue turn around the number of clusters relative to the number of total private schools that we're seeing in those private schools and also just the overall number of cases and those clusters eso we're working very closely with our partners in private schools to try to ensure that they are following the protocols. And as I think you all are aware. And I know Becky Plancher we'll talk about in the end. We do have. Ah, Titan. Mass requirement and mass are required now for all Children. Um, ages five and up in both our private and public schools and in all public settings. So next slide, please. All right, we're going to really focus our time today on two things I think are very important for you all to know about and be aware of. Azzawi. Continue. Thio, build our tools in our toolbox. Um to come back. Co vid one is a new antigen testing pilot that I'm going to talk about. And I'm going to turn it over to Dr Tilson, who will talk about vaccines generally and where we are a state and as a nation. And what we see is are, of course, all of our hope on the horizon for our light at the end of the tunnel for addressing Coben. And I do want to say with me today I'm joined by not only Dr Tilson um, but also by Dr Aditi Moloch, who's done a lot of our work on our an agent testing and our overall covert response. So I don't think you've met Dr Malik. But welcome to Dr Malik and, of course, Becky Blanchard, our senior, uh, our senior policy advisor for all things early childhood in K 12. So moving on thio are antigen test pilot. Just a little step back. A reminder about what we know about the different kinds of tests that we have for co vid. I think all of you are pretty familiar with the molecular PCR based tests. Um, these are our most sensitive tests. The molecular PCR tests are the kind of test you would get if you go to CVS or Walgreens and get a test. And again, those air are most sensitive tests. Um, And then there are antigen tests, which again really focus on, uh, excuse me, excuse me. Which really focus on detecting the presence of viral proteins and and their their most useful and folks who are symptomatic. And that's why when we talk about this pilot, we're going to talk about symptomatic and close contacts when we're talking about using these antigen tests and these air what we're calling the These are the been X now tests in this case antigen test. And then there are also antibody tests which detect prior infections. So these air thes air detecting prior infection, and then they're not useful and doing, uh, testing or screening for co vid next slide, please. Okay, I think, as you all are aware of, we have put out testing guidance previously on DWI are staying with this testing guidance. And so what? What we said is, for schools who are considering doing testing other is not a requirement for schools. Thio test other students or staff that are key recommendation here would be to recommend symptomatic students and staff be tested and that close contacts be tested and that later another option to consider would be screening asymptomatic people. And and likely they're most likely starting with staff. Um, the adults in counties that are red or orange and our county alert system, which I think all of you are not familiar with. Next slide, please. Okay. And this slide just gives you a little bit of a look at, um, where we're seeing most testing occur right now in our population ages 0 to 24. Next slide, please. All right, So we are going to be launching a pilot with some free antigen testing that tests that we received from the federal government. North Carolina will receive just over three million tasked by the end of 2020. And, uh, K 12 schools are among the priority populations for these tasks. They're not the only population, but they're among the priority populations for using these tasks. And as I mentioned these bionics now, an urgent tests are really designed for rapid diagnosis of active infections within 5 to 7 days of symptom onset. And as I also mentioned, they're less than sensitive than the PCR molecular tests. So what we see with those is that there's a greater chance of false negatives, which is why we're specifically again focusing on piloting, um, this thing, this with symptomatic and close contact students and staff and who can perform these tests? We did. It does need to be someone who's undergone the training from by next now, and but it does not need to be a health care professional, So I'm gonna talk more a little bit more about that in in a minute and all the facilities that perform these tests must have a clear certificate of waiver and must meet clear regulatory requirements. I'm not going to get into that in detail, but if folks do want to talk about that, when I when I finish Dr Malik and talk a little bit more about what that exactly means, um, it's not as scary as it sounds there. There's a lot of ways to make that happen, and the testing personnel must collect and report patient and result information. Next slide, please. Okay, so a little bit about the pilot for public schools that were just about to launch eso. We are calling it a pilot because there's a few things that we know are true. One is we know that schools have a lot on their plates right now, so I just want to acknowledge that Onda again, this is just another potential tool in the tool. Pop to a box that schools who want to want to pursue this pilot already have an interest that probably already started thinking about it might use. So it's it's not a requirement. It doesn't mean that everyone needs to get started now. We really do want to do a pilot because we think we're gonna learn important lessons about how the logistics work, about what kinds of questions there are about what kinds of additional guidance is needed. So we're going to start with a pilot. Um, and folks will have an opportunity to apply for this pilot and partnership with their local health department. And again, I just want to emphasize that the focus here is going to be, um, staff who stay staff who have staff and students who have symptoms or close contacts. So who can choose to participate if you'll just stay with that last side just for a second? Thank you. Um, just to be really clear, it's all and see public school districts and charter schools that are operating in person. Um, it is local health departments or other partners interested in providing these anedge and test for schools. And again, our expectation is that there will be a partnership Onda again. Our expectation is that this will probably pilot will be most suitable for folks for school district's who have already been thinking about this and again There. You can see the requirements, um, for the pilot and we can certainly talk more about them. But there are some requirements again, the training, the clear certificate of waiver. Um, they obviously have to have PPE and the capacity to dispose of the medical waste and obtain the parental consent to test. That's very important on Ben. There are some additional reporting requirements for these tests. That slide, please. So there is a very assertive timeline here to move forward with this pilot because we really want to get this fielded and get these tests being used again as another tool in the toolbox for for schools in Combating Cove in 19. So they the goal is for the test to arrive to selected District's no later than December 14th. So that is the goal. And how can partners apply? And there will be an application forthcoming? Um, I think today, or if not later this week, and Becky and the D. T can talk more about that, Um, but they will submit their application to the local health department expressing interest, and then the local health department will submit all materials to DHHS. So again, I talked a lot about how this is a partnership, and it's really important to emphasize that it's gonna be really critical, but the dress district work hand in hand with their local health department. Next slide, please. So there's a lot of different ways a pilot might might work. Um, probably the most obvious. And what folks probably think about most in their head is example. Three, which is where the school is providing their own testing on site. There are a lot of advantages to that model in terms of, um, access of of staff and students who are right there. But obviously it's a it's an added responsibility, so there's some other opportunities as well. Um, there could be an opportunity for the school district, a partner with the local health department and and then for there to be some kind of mobile school based testing locations. Um um ah, school district. My partner with a local hospital, um, to make that this pilot work. So there are a couple of different and we were happy to talk through potential opportunities there, and I think, probably back in a d. T. Have some additional models that they might talk about when we get to questions and answers. Next slide, please And then again, just here's a little little graphic depiction of the overall timeline for this pilot. A zoo. See there. Hopefully we'll be selecting the pilots and getting tests out in mid December. And then based on what we're learning, we will quickly move Thio increasing distribution to more schools that are wanting to participate. And I do want to emphasize here if supplies are available. I think everyone is aware we have a limited supply of these tests now. And all of us are, I think, hoping for and, um, anticipating additional federal support for both testing for K 12 schools and beyond, among many other things that we're hoping there will be another federal package for next slide, please. Okay, before we move on to vaccines, I want to stop here and give folks an opportunity to ask any questions they have about the K 12 antigen testing pilot. And then we'll move quickly into a presentation on vaccines, which I know you all are very excited about, as are we. So are there any questions at this time about the about the testing pilot? Oh, questions from my colleagues chair Davis. I do have a question This is Olivia. Dr. Jackson. Done. The testing is very interested in my question. Is this, um what is the in purpose of the testing? Is it to for further therapies or just how will the data be used? That's a great question. And actually, I'm gonna ask Dr Tilson to take that one. Yes, I'm happy to. Can you hear me? I can't. Wonderful. Yeah. So the point about testing will be early identification of people who may be positive so that we can then more quickly put in those control measures to prevent spreads through the schools. So that will be one of the main. The main advantages of that of the testing, As you know, for especially for Children and healthy adults, Um, that they typically don't have a lot of medical, um, complications. So it wouldn't be starting medication early on. But what's really important is early identification of positive again so that we can then do those control measures the isolation and the quarantine to prevent further spread throughout population and one follow up. If I'm may chair Davis, my follow up would be our our other states. Is North Carolina on the cutting edge Or is this going on in other states? The testing, Great question as well. And I'm actually gonna ask Dr Malek Thio, who's really been leading this effort to talk about that. There are a lot of other states doing this, But, Dr Malik, you want to talk more about that? Happy to thank you, Susan. And thank you for the question. Um, I will say both. North Carolina is both on the cutting edge of this, but there are other states that are doing this. Um, So when these tests were announced by the federal government, one of the areas or populations that were specifically called out for the use of these tests were K through 12 schools. Eso I'd say other folks. Other peer states that are on the cutting edge of using these tests in school settings are, um, Massachusetts in Arkansas in particular. But I would say there's on the order of at least like five plus states that have really channeled their use of these tests to those settings. All right, very good. Thank you very much. Chair Davis, this is jail cam net with candidates. Um, yes. So my question would be if the district is interested in applying for this pilot, Would they be expected Thio to do the testing throughout all the schools in the district? Or would they be able to focus on, say, a particular age group or decide where the tests they're most needed within their district? Another great question. And I'm actually gonna ask Becky Plancher that we're gonna We're gonna do it around Robin to answer that question. Okay, Thanks so much, Susan. And thank you for that question. I think that Dr Malik is gonna agree with my answer. But there are a variety of different ways this pilot could look depending on the needs of a particular district. Um, uh, Susan showed that slide that had those three different examples just of kind of from a bird's eye view how this could look. But even within that, I imagine that exactly your your thoughts. Um, if a district had a particular need, um, within an age group, or they wanted to prioritize a specific age group as long as they're focusing on testing symptomatic students or students who are close contacts of someone who has tested positive for co vid that would meet the criteria along with meeting the other requirements to be a part of the pilot. But I don't see any reason why not. Thank you. Any other questions I'm testing before we moved to vaccines? Yes. Share. Davis, I have a question. This is Donna took the Rogers. Yes, Dr Tipping. Roger. Just a quick question about the parental consent. Is this something that you will have tohave prior to testing? Um, if you're gonna do whole schools are certain age groups. Or are we not concerned about that? I'm gonna let Becky plants your dad answer that one as well. Um, or Dr Malik, I'm happy to chime in. Thank you for the question. The short answer is yes. Consent would be required prior to testing any student, and similarly, And this this is in the application materials that will be releasing shortly. Um uh, there would also need to be a mechanism to notify a parent or guardian if a test is done on a student as well. What the results of that test is because as a doctor, Tilson may have mentioned in some earlier comments. The result of there's there's some next steps depending on whether that test is positive or negative. Thank you. You're welcome. Other questions during non back to you, Chief Deputy. Thank you, Chairman Davis. And I am now gonna turn it over to my wonderful colleague Dr by Bhakti Tilson, our state health director, to talk about vaccines. Thank you. Very happy to be with you here this month. I think we put a little bit of a primer last month saying that we would be happy to come back. Um, as we look forward to our next phase of our coded response a little bit of the light of the end of the tunnel and what we expect will be a really important arrow in our prevention quiver to get us all out of the pandemic, which is, um, the vaccine. So we wanted to give you from high level level views off our vaccine plan and happy to come back and get into more granular details on as we move forward. So first I just wanted to put where our vaccination plan is in our whole menu of our covert response we've talked about before. We really have to get it. This pandemic, in a multifaceted way, we have our prevention arm are testing and tracing arm that we just talked about and the isolation and quarantine arm, which is the reason you test is and to put into those control measures. So we have now all very related of our of our approaches. Thio our control of this pandemic and so in our prevention arm is now our newest tools be preparing for And then when we relatively soon we'll have some vaccine being able. Thio, utilize that tool. Um, next five, please. Wonderful. So as we move through our vaccination plan, we at the same way that when we talked a couple months ago that one thing I know for sure is that things will change on that. We know that some of the details, some logistics, some of the guidance, some of the data will absolutely be changing. But what? We wanted to be sure that we were routed in principles that would stay as we are moving through our agile design of our vaccination plan. And so just to make sure we're all grounded in our guiding principles one we want to be sure that all North Carolinians have an equitable access to vaccine and so equity is a really important lens, and you will see that when we go through a little bit of our prioritization and really having that that equity and the maximization of benefits, as we think through our vaccination distribution. Second, we have tried to be very inclusive in our planning and distribution and engaging, Um uh, many other Our local and state governments are private partners, Um, and especially engaging folks from our historically marginalized population as we know the pandemic has, um, create more of an undue burden on a historically marginalized populations. So really making sure that we're tapping into the leadership, um, of those populations were trying as much as possible to be as transparent and have frequent public communications as much as possible. Um, this is one piece of that in an area has been this whole pandemic of rapidly changing data, um, and information we feel the most important way toe to build trust of all of us is being sure we're communicating as much as possible. We will be using our data to not only guide in that transparency, but also to guide us in our decision making and ensure that we are having that equity lens. And as we get through and moving into more implantation of our vaccines, we will be as we start having more data, um, be putting that are vaccine data out publicly as we are as we're getting that. And then finally, again, as I allude to that, we expect there will be continue adjustments and quality improvement. Um, um, work as we move forward to ensure that we're being appropriate stewards of all of our resource Next slide. Very, very, very briefly. I wanted to go up about 30,000 ft and just understanding how this covert vaccine vaccines forgive me, um is being developed because we what we have heard many times is there's a concern about how the speed of the vaccine development, Um and there's concerns about the safety, um, piece of the speed of the vaccine development. And so what I wanna go through is, in very broad terms, the process for this vaccine development and really hit on that. All of the safety and data measures have all been in place. There has not been a short cutting of a data and safety, but there's been other ways of part of the process that's been able Thio to produce that speed. So I just think this is a really important foundational question because what? That's what we've been hearing as people are concerned about safety because of the speed. So just a couple elements in here I wanted to highlight one. That part of the way that vaccine and is anticipated to be out more quickly than usual is, ah, parallel process of the clinical trials. So that is all of the research and the clinical trials that that look at Does it work and is it safe at the same time? Is all those clinical trials been going on? Production of potential vaccine started, so it was a parallel process instead of a serial process. So typically, you wait until the end of the clinical trials and then you start producing vaccine. The federal government decided this was too important, and so they are us. We were all our government, um started producing vaccine at the very beginning whenever the all the clinical trials were starting, knowing that was an enormous financial risk. But the federal government backed that financing, knowing that vaccines that for whom there isn't good data and efficacy data those vaccines would not be used, but that for those clinical trials where there is good safety and efficacy data, there would be vaccine ready. So it's a really important piece of the policy, and decision making is the parallel process of production at the same time as the clinical trials. Second on the top row, you will see these are the regular stages got go through clinical trials, Phase one, Phase two and Phase three all of the same path, um, have been taken for this, this vaccine development as other vaccine developments. But one way that they did increase speed is that as soon as they started phase one, they were already planning for phase three. So there's no gaps between the phases. The other really important piece, I think, in phase three clinical trials. This is where we really get at. Does the vaccine prevent people from getting sick, getting the infection or getting really sick? And because the space is critical trials, you have a lot more people. You can get a lot more information on safety. Um, and so really, really important feature of these clinical trials is that, um, many, many, many more people have been enrolled in volunteered for these phase three clinical trials, and it's typical. Usually it's only about three or 4000 people are so in phase three clinical trial. In these it's 80,000. 10 times as many people have been involved in those phase three clinical trials, which has really helped speed up getting that information on safety and then also effectiveness s so that is another way that they were able Thio speed that up again. Not any short, um, shortcuts of safety and efficacy, but just the way that the trials were planned and then the number of people enrolled. That Orange Arrow is the phase that will be heading into, especially with the two front runners the size of the Madonna. Um, that they will. Once those clinical trials are done and they have the least are those two main ones have come to the end of their trials. Then there is, as there is always external review by by scientists that look at all of that data that will be happening, um, in in the next week or two, um, for the fighter and Madonna, that's the famous as typical. And then also, there's another review body at the Centers for Disease Control. Um at that's the Advisory committee on immunization practice. So all of those review bodies that are typical will be happening as well. So I just spent a little bit more time on the slide because I think it's really, really, really, really important for people to understand. How is it that vaccine got more quickly and it's not because of compromising the safety or efficacy data? Okay, next slide, please. Having said that, though, having said that yes, vaccine will be available more quickly than usual, I think it's really, really important to have expectations settings. And for some reason, uh, some of the words did not carry over in this slide. There is words in that in that typically, those words in that first bucket. But the really important piece of this is, although we will have some supply ready to go. Once all of the scientists review that safety and efficacy data, we will have very, very limited supply in the beginning. We may have some supply as early as a week or two in North Carolina, but very small supplies, um in the beginning. We do not anticipate that we will have enough supply for the majority of people, Really, until the spring. I just want to make sure that, uh that's a really important expectation setting very, very limited supply in the beginning. But we will be getting more as we go forward. And so it'll be incredibly important to continue our prevention work are three W's until we have enough vaccine for the majority of people. And again, that probably won't be until later in the spring. Okay, next slide, please. Ah, little bit about our prioritization. Because people have been asking, um, hourly. Where do when When is my turn? When would I fit in? Where do I fit in terms of prioritization plan. Um, so sensitive who? Maybe troll our websites. We did post our plan back on October 16th. And so that is available to the public with very, very, very granular data on our on that prioritization plan. We based it on the National Academy of Medicine. They had a framework for equitable distribution of vaccine, and we also, um, it was refined, and we got great input from, um, the North Carolina Institute of Medicine convened an independent vaccine advisory committee for us. Um and they gave us great feedback and guidance on that prioritization. We will actually just made a new adjustment yesterday because the advisory committee on immunization practice from the CDC just put out some recommendations for some of that prioritization. So we will be revising that prioritization based on some of those federal recommendations as well. I think it's really important to understand the principles that were adopted for the prioritization again equity maximization of benefits. And we're talking that of some of the decisions of who would be prioritized first. There's also a component of operational feasibility and thinking through how we're gonna actually do this. I'm making sure we're having a principle of do no harm. And as I alluded to, we expect there will. This will be some interests and some adjustments. As we get different data from the popular from the clinical trials. What population is it safe and, um, and efficacious for andan what further federal guidance we may have. So they will they My, uh, expectation will be some adjustments in the in the priority scheme. On the next slide, you will see where we are today, but again, there may be some adjustments. Um, the phase one A. So they're very, very limited supply that we get in the beginning. We those will be a prioritize for healthcare workers at very high risk of Covad 19 exposure So caring for people with cova 19. We'll also be prioritizing people in our nursing homes or long term care staff and residents because we know the risk of death is much higher higher in that population. So those will be the beginning when we have that very limited supply, where we'll be directing it the next phases again, this is a max emission of benefits. Is that adults that have very high risk of complications and clinical severity with this virus that we will be prioritizing those people next to protect, protect them from getting really sick and protect from death. Um, and what we'll be doing is operationalized prioritizing getting to providers that can get to those populations that have not only a high risk of severity, but also a high risk of exposure. So that means our people in congregant living settings on and those are health care workers and then also our frontline workers that have a high risk of exposure. And so for this group, you will see where I bowled ID. We do. Um, consider our education staff are frontline workers because they were there in person working and have a higher risk of exposure. So education staff that have, uh, they're high risk of complications. And we're using the CDC definition of those medical conditions that put someone specifically at risk for co vid um, clinical severity, those education staff that are high risk. They would be in that early phase that phase one B in phase two, you will see we have are people who are less risk of that clinical severity. But still it increased risk of exposure. And so again, you will see that's where education staff, um, sits in a zoo. Well, those without to to a car, chronic conditions, but at higher risk of exposure because their frontline staff, that's where they would fit in. In phase three, I bowled ID um, K 12 students, and this is a really important piece. I think currently the clinical trials have not been enrolling Children. Um, some of the some of the trials are starting to enroll from adolescents 12 and up. But our our K five, um, that those younger students and pre and pre k those air not in those people are not enrolled in clinical trials yet. So we will not have data on Children. So I do not expect them to be in the beginning. And we will probably have to hold off on being able to immunize Children until we have the data or the recommendation. So it's a tentative phase three, depending on the data. So I just wanted Thio Make that a little clear is where our education staff and students would fall into our prioritization schema when a zai alluded to We will have very limited supply before the end of this year but probably will not be getting to a lot of phase two or phase three until next year. Um, and probably not a lot until the spring. And then the very last slide I think I have on this. If you go to the next slide, please. Yeah. Uh, well, it's not moving on my sheet, but but I will just talk through the next slide while we're move that up. Is our communications really, really important. As I was alluding to that, I want to be sure that as this rapidly evolving, uh, nation plan that we are communicating as much as possible. We have some principle very good. We have key principles of our communications that again early, transparent and frequent communications. We want to really be sure that people can trust the information that they're getting, especially from us and from the local health departments. We really wanna be sure people are understanding the benefits and risks of this co vid vaccine. Critically important because what we want is people, then to make an informed decision for themselves based on reliable, trustworthy information. And then once we do have enough vaccine for folks and it's really getting out, we want to be sure people will understand where they could get the vaccine. Um, on the bottom of the slide is our vaccine web page. I would really encourage you to go to that vaccine Web page. Our whole plan is there, and we also are putting out some communication tools that please, I would say, Take them and share. We have that same name of Infographic that I had talked about, how the actually co The vaccine has been developed. We have a vaccine. 101 slide deck that just talks through. What? What is even vaccines do? What is, um what is the how the vaccines work on and then talk through and grand, more granular detail how this vaccine was developed and we also have weekly updates again. The information is changing so quickly that every week we are putting out a weekly update of where we are. What's the status of clinical trials? What do we know about safety and efficacy that will be updated every week? I would really, really encourage you to go to that website and get the updated information and share it amongst your stakeholders as much as possible. So with that, I'm gonna stop. There is, you know, a jillion more details in there. Um, but happy to take any questions that you have on that. And then we also are very happy to come back. Um, A such as you want to get more into more details on this? Because I do see, this is critically important. Um, as as our way out of this pandemic, I want to be sure people have all the information from the with stopping field questions. This is Mr For, uh, could I Could I just hopping and asking, Actually make a statement really quickly. Thank you. Thank you, Mr Chair, I am so appreciative of the continual communication and the overview, especially as we find ourselves on the precipice of a vaccine. And so you're overview of all of the information and process that went into that eyes very comforting and especially talking about why, uh, individuals should feel comfortable that it is safe. I'd be remiss if I didn't say that for a lot of people. And I'm gonna be very specific here. A lot of black people I would consider myself as part of this number. Our concerns are rooted and not because we're category the anti vaxxers, but because there's a very real and lived history. Uh, you know, of breaches of trust, you know, things such as the Tuskegee experiment. The story of Henrietta lacks most recently the flint water crisis. These things that just lead to a lack of trust. And so, as we encounter various communities reactions to this, I do just want to clarify that a lot of this is not, um, to diminish all of the work that went into it. Rather, it's a historical trauma, right? That that has caused a lot of us to just have an inherent distrust off how these things impact us. And so, however that could be worked into the messaging on responded to preemptively, I think would be an incredibly important step as part of the essential equity focused approach to disseminating this. So I just wanted to get that on the record, because again, I wanna make sure that we are all coming out of this A Z best we can. But I do recognize the unique differences on peculiarities that our histories have that informed this experience. And so thank you. I just want to mention that the questions you mention my colleague, Mr Chairman Wind L Mr Hall. Thank you, Sarah. The the storage issue with the with the vaccine. I've been reading where there has to be a special storage container. That's nine minus 95 degrees to store the vaccine in. If that is true, will that be presented to all the We will all the health department have that, uh, storage capability? Yes, sir. Thank you very much. I'm happy to take that, but before I will definitely get to that. But I want to go back to that prior comments because that is critically important. 100% the historical trauma, critically important. And e think the directly impact our our ability for this equitable distribution. So thank you for that. We did not have time to go into that. And we're happy to bring that back. Maybe to the next time of how we're trying to address some of that historical trauma we have really engaged again. Are we have, Ah, historically marginals, um, work group that is informing up. If you look at the makeup of our advisory committee, we have folks on health experts and health equity and a lot of advocacy for a number of groups. In some of our communication work, we are intentionally working with minority populations are historically marginalized populations understanding the barriers, understanding the fears, understanding what they would need to feel safe, that they have that information. We are thinking through who are trusted voices. Right. Here we go. Um, is it our faith leaders? It is. Our black physicians are black physicians are incredibly trusted voice. They have taken a big leadership in that role. Old North state is our our black physician association. So it is incredibly important issue. And we are. I'm sure we're not doing as much as we need to, but we're intentionally trying Thio address that issue and again, not with no emphasis of coercion, but making sure people have what they need to feel. That they have the information to make an informed decision from the self so critically important piece Getting to a cold storage. Also very critically important piece. Uh, there are there, Will. Right now, there are two main vaccines that we expect to be coming first, but there will be other vaccines. I expect coming down the road. Each of them will have different stores. Different logistic, um, issues the Fizer vaccine, which is the one we expect to get first. If all goes through, that is the one that needs that ultra cold storage down to the negative. 75 degrees. Healthiest, the modern A vaccine which again, if all goes as well, we should be getting about a week after the fighter vaccine that one does not have an ultra low cold storage, Um, requirements is just a regular freezer requirement. Um, and it will come in smaller allotments, so that one is gonna be a lot easier. Um, for us to be able to distribute the fighter is a little bit more tricky. Um and so there's a couple things to that. We do have places across the state that have ultra local storage, permanent ultra local storage. We've identified that we know those. Also, the fighter will be shipped in a shipping container. Um, that keeps it at that negative 70 and they'll be resupplies of dry ice to keep it at that at that cold storage. Because of the complexity of that, our current plan is that the fighter vaccines will go to our health systems. Um, where it'll be more easy for them Thio store and utilize that in a lot of them do have that storage the Madonna, which is the easier one. That is the one that we plan to be shipping then to the health department, to our community providers, where they won't need all of that extra storage. So that is our plan for that. And then we'll have to see the storage requirements for other ones that come down the road. But we think we're OK with the storage requirements, and and they all won't need that. Ultra local justifies. Er so that was a lot of people in there, but thank you for that. But I really was concerned about the visor being It's the first one coming out and then, yeah, requirements. Hey, and it being available, uh, to our rural areas of the state also. Yes, sir. But we again, we we think the fighter will get first. But the week after at least what we've been told right now, the week after we might we should get shipping for the Madonna and actually higher quantities of Madonna. And we should get higher quantity of Madonna and it can ship in smaller amounts with the fighter. It's almost about 1000 doses.